Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Stock-based compensation expense | 6,553 | 2,094 |
| Non-cash operating lease expense | 489 | 491 |
| Amortization of discount on marketable securities | (200) | (697) |
| Depreciation expense | 154 | 159 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 740 | (559) |
| Accounts payable | 1,209 | 3,554 |
| Accrued expenses and other current liabilities | (3,463) | (4,320) |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's D&A?
- Sionna Therapeutics (SION) reported D&A of $154K in Q1 2026.
- How has Sionna Therapeutics's D&A changed year-over-year?
- Sionna Therapeutics's D&A decreased by 3.1% year-over-year, from $159K to $154K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Sionna Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude